Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Rare variant of large effect in BRCA2 and CHEK2 affect risk of lung cancer.
Wang, Y, McKay, J.D., Amos, C.I., et al. Nature Genetics, published online ahead of print June 1, 2014.
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, Van Asperen C, Kiemeney L; The IMPACT Study Collaborators, Easton DF, Eeles RA. British Journal of Urology International. Volume 107(1), p. 28-39. January, 2011.
Screening in GI cancers: The role of genetics
Stoffel, EM, “,” Journal of Clinical Oncology, Vol. 33, No. 16, pp. 1721-1728, June 1, 2015.
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
A Mitra, C Fisher, C S Foster, C Jameson, Y Barbachanno, J Bartlett, E Bancroft, R Doherty, Z Kote-Jarai, S Peock, D Easton, The IMPACT and EMBRACE Collaborators and R Eeles. British Journal of Cancer. Volume 98(2), p. 502-507. January, 2008.
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers
The Icelandic BRCA2 999del5 founder mutation was strongly associated with rapidly progressing prostate cancer with poor prognosis.
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T, Kanji, ZS, Epelbaum, R, et al., British Journal of Cancer, Vol. 111, pp. 1132-1138, September 9, 2014.
Expand+BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Tomas Kirchhoff, Noah D. Kauff, Nandita Mitra, Kedoudja Nafa, Helen Huang, Crystal Palmer, Tony Gulati, Eve Wadsworth, Sheri Donat, Mark E. Robson, Nathan A. Ellis and Kenneth Offit. Clinical Cancer Research. Volume 10, p. 2918-2921, May 1, 2004.
BRCA Germline Mutations in Women With Uterine Serous Carcinoma-Still a Debate
Lavie, Ofer MD; Ben-Arie, Alon MD; Segev, Yakir MD; Faro, Jonathan BSc; Barak, Frida MD; Haya, Nir MD; Auslender, Ron MD; Gemer, Ofer MD. International Journal of Gynecological Cancer:
December 2010 - Volume 20 - Issue 9 - pp 1531-1534
Article suggests an association between BRCA mutations and uterine serous carcinoma.
BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer
Bethany L. Niell, Gad Rennert, Joseph D. Bonner, Ronit Almog, Lynn P. Tomsho, and Stephen B. Gruber. Journal of the National Cancer Institute. Volume 96: p, 15-21, January 2004.
Melanoma Susceptibility Genes and Risk Assessment
Marzuka-Alcala, A, Gabree, MJ, Tsao, H, Methods in Molecular Biology: Molecular Diagnostics for Melanoma, Vol. 1102, pp. 381-393, 2014.
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer
Tomas Kirchhoff, Jaya M. Satagopan, Noah D. Kauff, Helen Huang, Prema Kolachana, Crystal Palmer, Hannah Rapaport, Khedoudja Nafa, Nathan A. Ellis, Kenneth Offit. Journal of the National Cancer Institute. Volume 96: p, 68-70, January 2004.
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary,
van Asperen, CJ, van Leeuwen, FF, et al., Journal of Medical Genetics, vol. 42, no. 9, p. 711-19, September 2005.
Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals
Thomas S. Frank, Amie M. Deffenbaugh, Julia E. Reid, Mark Hulick, Brian E. Ward, Beth Lingenfelter, Kathi L. Gumpper, Thomas Scholl, Sean V. Tavtigian, Dmitry R. Pruss, Gregory C. Critchfield. Journal of Clinical Oncology. Volume 20, Issue 6: p. 1480-1490, March 2002.
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Marcia S. Brose, Timothy R. Rebbeck, Kathleen A. Calzone, Jill E. Stopfer, Katherine L. Nathanson, Barbara L. Weber. Journal of the National Cancer Institute. Volume 94, Number 18: p.1365-1372, September 18, 2002.
Cancer Incidence in BRCA1 Mutation Carriers
Deborah Thompson, Douglas F. Easton, the Breast Cancer Linkage Consortium. Journal of the National Cancer Institute. Volume 94, Number. 18: p. 1358-1365, September 18, 2002.
Risk of Endometrial Carcinoma Associated with BRCA Mutation
Douglas A. Levine M.D., Oscar Lin M.D., Richard R. Barakat M.D., Mark E. Robson M.D., Deborah McDermott M.S., Lesley Cohen M.S., Jaya Satagopan Ph.D., Kenneth Offit M.D. and Jeff Boyd Ph.D. Gynecologic Oncology. Volume 80, Number 3: p. 395-398, March 2001.
Cancer Risks in BRCA2 Mutation Carriers
The Breast Cancer Linkage Consortium. Journal of the National Cancer Institute. Volume 91, Number 15: p 1310-1316, August 4, 1999.
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations
Shu CA, Pike MC, Jotwani AR,et al, JAMA Oncology, June 2016